Organization (Industry)
Tillotts Pharma (Switzerland)
ClinicalTrials.gov lists Tillotts Pharma (Switzerland) as lead sponsor of 10 trials. It has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Tillotts Pharma (Switzerland): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (6)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Inflammatory Bowel Diseases | 6 |
| Colitis, Ulcerative | 4 |
| Crohn Disease | 2 |
| Inflammation | 2 |
| Acute Disease | 1 |
Showing 5 of 6 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 2 |
| 2012 | 2 |
| 2011 | 1 |
| 2010 | 2 |
| 2009 | 1 |
| 2003 | 1 |
| 2002 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Mesalamine | 2 |
| Epanova | 2 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | not enough data |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Advances in therapy | 2 |
| Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2 |
| Alimentary pharmacology & therapeutics | 1 |
| Gastroenterology | 1 |
| JAMA | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 33 | 16 | 2025-09-23 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Tillotts Pharma AG | Ziefen, CH | EMA, Health Canada | |
| Tillotts Pharma AG | Rheinfelden, CH | EMA, Health Canada |
Latest dated events (45)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-02-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-01-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 45 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD9 | Trial sponsor | Named in trial exclusion criteria |
| CD9 | Trial sponsor | Mentioned in trial text |
On Scientist.com
Tillotts Pharma (Switzerland) is listed as a research supplier in the Scientist.com network.
Service areas
Tillotts Pharma offers contract manufacturing services including formulation development, stability testing, and clinical trial supply services.
- Website
- www.tillotts.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Tillotts Pharma on Scientist.com
For prices, more details, or to contact Tillotts Pharma, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.